DELLPHI-305
Start here
Three Chinese-led oral presentations at ESMO 2026 delivered updated results across MET-amplification resistance, non-small cell lung cancer, and thymic carcinoma. In a randomized phase 3 trial (NCT06110663) enrolling 314 patients, a dual-TKI regimen significantly improved progression-free survival in MET-amplification resistance, with independent-review-committee-assessed median PFS of 6.2 versus 4.4 months (HR 0.601, P<0.001). CS2009, meanwhile, showed preliminary activity in the evaluable first-line population with PD-L1 TPS of 50% or higher, with an objective response rate of 81.3% and a disease control rate of 100%. Ivonescimab data in thymic carcinoma were also presented as part of the session. Full details of the ivonescimab and remaining CS2009 results have not been reported in the summaries so far.
Written by a model from the reports · updated 4 hours ago
Developments
- Oct 23 16:00 · 1 reportESMO公布肺癌及胸腺癌三项试验结果mp.weixin.qq.com · ESMO 2026 Chinese Orals: Dual TKI Improves MET-Amplified Resistance, CS2009 and Ivonescimab Report NSCLC and Thymic Carcinoma Data
- Oct 16 05:07 · 5 reportsFive lung cancer trials to watch at #ESMO26: DeLLphi-305 KRAScendo 1 SAFFRON OptiTROP-Lung04 OptiTROP-Lung06 Encouraging signalsx.com · @BalazsHalmosMD and @DylanFortman preview 14 lung cancer abstracts at #ESMO26, including DeLLphi-305 (LBA3), Krascendo 1 (LBA5), SAFFRON (LBA6), OptiTROP-Lung06 (LBA66), and PERSEE…
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comESMO 2026 Chinese Orals: Dual TKI Improves MET-Amplified Resistance, CS2009 and Ivonescimab Report NSCLC and Thymic Carcinoma Data
Three Chinese-led oral presentations at ESMO 2026 updated data on MET-amplification resistance, NSCLC, and thymic carcinoma. A dual-TKI regimen significantly improved PFS in a randomized phase 3 study: NCT06110663 randomized 314 patients, with IRC-assessed mPFS of 6.2 vs 4.4 months, HR 0.601, P<0.001. CS2009 showed a preliminary ORR/DCR of 81.3%/100% in the evaluable first-line PD-L1 TPS≥50% population.
Heat trend for this story
Heat now 12·Peak in the comparable set 29 (Oct 21 22:00)·Change over 24h in the comparable set +9%·Participants now 5
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.